|
04/21/11 |
|
|
|
|
|
|
FDA Grants Orphan Drug Designation for Nektar's
Investigational Drug, NKTR-102, for Treatment of Women with Ovarian
Cancer |
|
|
|
|
|
Merck and Sanofi Pasteur Initiate Phase III Study in the
United States of Pediatric Combination Vaccine to Help Prevent Six
Infectious Diseases |
|
|
|
|
04/20/11 |
|
|
|
|
|
|
|
|
|
Gilead and MicroDose Therapeutx Announce License and
Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory
Syncytial Virus |
|
|
|
|
|
Amgen's First Quarter 2011 Revenue Increased 3 Percent to
$3.7 Billion |
|
|
|
|
|
Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent
Ongoing Earnings-Per-Share Growth in First Quarter |
|
|
|
|
04/19/11 |
Sangamo BioSciences Announces First
Quarter 2011 Conference Call and Webcast
|
|
|
|
|
|
|
|
|
Genentech: FDA Approves Rituxan
Plus a Steroid for Use in Severe Forms of Vasculitis
|
|
|
|
|
|
Biogen_Idec
FDA Approves Rituxan Plus a Steroid for Use in Severe
Forms of Vasculitis |
|
|
|
|
|
Biogen Idec Receives Positive Opinion from the CHMP and
Authorisation from Health Canada on AVONEX PEN |
|
|
|
|
04/18/11 |
|
|
|
|
|
|
|
|
|
Lilly Declares Second-Quarter 2011 Dividend
|
|
|
|
|
04/15/11 |
Lilly Receives Complete Response Letter From FDA for Liprotamase for the
Treatment of Exocrine Pancreatic Insufficiency
|
|
|
Genentech: FDA Approves ACTEMRA® (tocilizumab) for the Treatment of
Systemic Juvenile Idiopathic Arthritis (SJIA) |
|
|
|
|
|
Regulatory Update: GlaxoSmithKline submits additional information for
candidate meningococcal and Hib combination vaccine |
|
|
|
|
|
Merck Commences Tender
Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
|
|
|
|
|
|
Roche gains positive CHMP opinion for the combination of Avastin with
Xeloda as a first-line treatment for metastatic breast cancer in Europe |
|
|
|
|
|
Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of
Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis |
|
|
|
|
|
AstraZeneca Initiates Phase III Clinical Programme
Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation |
|
|
|
|
|
Merck Commences Tender Offer for all Outstanding Shares
of Inspire Pharmaceuticals, Inc. |
|
|
|
|
04/13/11 |
Life Technologies Announces an Automated Sample Preparation System for
its Ion PGM™ Sequencer
print |
|
|
|
|
04/12/11 |
Novartis drug Afinitor® recommended by FDA oncology advisory committee
for approval to treat advanced NET of pancreatic origin |
|
|
|
|
|
Bruker Announces Two Major Orders for Novel High-Field 395 GHz Solid
State DNP-NMR Systems in Canada and Germany
|
|
|
|
|
04/11/11 |
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of
Dimebon in Huntington Disease |
|
|
|
|
|
Novartis discontinues clinical trial of Tasigna® for investigational use
in newly diagnosed patients with unresectable and/or metastatic GIST |
|
|
|
|
|
Novartis discontinues clinical trial of Tasigna® for investigational use
in newly diagnosed patients with unresectable and/or metastatic GIST |
|
|
|
|
|
Novartis discontinues clinical trial of Tasigna® for investigational use
in newly diagnosed patients with unresectable and/or metastatic GIST |
|
|
|
|
|
FDA Approves Merck's SYLATRON™ (peginterferon alfa-2b) for Injection, a
New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal
Involvemen
|
|
|
Novartis therapy GilenyaTM reduced the risk of MS disability progression
regardless of treatment history or disease severity, new analysis shows
|
|
|
Biogen Idec Announces Positive Top-Line Results from the First Phase 3
Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
|
|
|
|
|
04/08/11 |
Sangamo Announces Pricing of Public Offering of Common Stock |
|
|
|
|
04/07/11 |
Sangamo Announces Public Offering
of Common Stock |
|
|
|
|
|
Roche announces positive Phase II
results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic
breast cancer |
|
|
|
|
|
Novartis sells global rights to
Elidel®, a medicine to treat atopic dermatitis |
|
|
|
|
04/06/11 |
U.S. Prescribing Information for
GARDASIL® Updated; Indication Not Granted for Use in Adult
Women |
|
|
|
|
|
GlaxoSmithKline and XenoPort receive FDA approval for
Horizant™RLS |
|
|
|
|
04/05/11 |
Merck to Acquire Inspire
Pharmaceuticals, Inc. |
|
|
|
|
|
Incyte Achieves $15 Million
Milestone for c-MET Inhibitor Oncology Program |
|
|
|
|
04/04/11 |
Thermo Fisher Scientific Extends
Cash Tender Offer for Dionex Corporation |
|
|
|
|
|
Two Novel Lilly Molecules Target
Genetic Mutations That Can Lead to Cancer |
|
|
|
|
|
Vermillion and Quest Diagnostics
Sign Agreement to Make OVA1(R) Available in India |
|
|
|
|
|
Depomed Appoints James A.
Schoeneck President and CEO |
|
|
|
|
|
Bruker Announces Closing of
Michrom Acquisition |
|
|
|
|
03/31/11 |
Biogen Idec and Knopp Biosciences
Announce Enrollment of the First Patient in a Global Phase III Study of
Dexpramipexole for ALS |
|
|
|
|
03/30/11 |
GlaxoSmithKline confirms Pronova
BioPharma reaches agreement with Apotex regarding Lovaza™ US patent
litigation |
|
|
|
|
|
Yale and Gilead Sciences Announce
Cancer Research Collaboration |
|
|
|
|
03/29/11 |
|
|
|
|
|
|
Lilly:
Effient® Added to Updated ACCF/AHA Clinical Guidelines
for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial
Infarction |
|
|
|
|
|
Bayer MaterialScience plans new production facility for
coating raw materials in Shanghai |
|
|
|
|
|
Agilent Technologies and National University of Singapore
Sign Research Collaboration Agreement for Lipidomics Research
|
|
|
|
|
|
FDA Clears Abbott’s i-STAT® 1 Wireless Point of Care
Testing System |
|
|
|
|
03/28/11 |
Abbott Introduces Micro-Implantation Cataract Suite |
|
|
|
|
03/25/11 |
FDA Expands Indication for ZOSTAVAX®, Merck's
Shingles Vaccine,to Include Adults Ages 50 to 59
|
|
|
|
|
|
BMS:
FDA Approves YERVOY™ (ipilimumab) for the Treatment of
Patients with Newly Diagnosed or Previously-Treated Unresectable or
Metastatic Melanoma, the Deadliest Form of Skin Cancer |
|
|
|
|
|
Second Lucentis Phase III Study Meets Primary Endpoint
for Improved Vision in Patients with Diabetic Macular Edema (DME) |
|
|
|
|
03/24/11 |
Portola Pharmaceuticals to Regain Global Rights for
Investigational Medicine Betrixaban from Merck
|
|
|
|
|
|
Agilent Technologies Expands Life Sciences and Chemical
Analysis Center of Excellence in India |
|
|
|
|
03/23/11 |
FDA informs Novartis of extension to US regulatory review
period for QAB149, a novel once-daily bronchodilator for treatment of
COPD |
|
|
|
|
|
Nordion announces Phase III clinical trial to evaluate
TheraSphere(R) for liver metastases in colorectal cancer patients |
|
|
|
|
|
Nordion announces Phase III clinical trial to evaluate
TheraSphere(R) in treatment of unresectable hepatocellular carcinoma |
|
|
|
|
|
|
|
|
|
|
|
Gilead Prices $1 Billion of Senior Unsecured Notes |
|
|
|
|
|
Phase III Clinical Trial of Gilead's Investigational
Elvitegravir Meets 48-Week Primary Objective |
|
|
|
|
|
Bayer CropScience to acquire US-based Hornbeck Seed
Company. Expansion and investment in southern US soybean seed market |
|
|
|
|
|
Amgen:
Prolia(R) (denosumab) Open-Label Extension Trial Showed
Continued Increase in Bone Mineral Density Over Five Years of Treatment
With Similar Safety Profile Observed in Pivotal Trial
|
|
|
|
|
03/22/11 |
|
|
|
|
|
03/21/11 |
|
|
|
|
|
|
BMS
Phase III Study of Investigational Compound Ipilimumab
Achieves Primary Endpoint of Improvement in Overall Survival in
Previously-Untreated Patients with Metastatic Melanoma |
|
|
|
|
03/20/11 |
Genentech Announces Positive Pivotal Phase II Results for
Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma |
|
|
|
|
03/16/11 |
Bayer MaterialScience strengthens position in carbon
nanotubes
License agreement with U.S.-based company Hyperion
concluded |
|
|
|
|
03/15/11 |
Second Phase III study of Novartis JAK inhibitor
INC424 meets primary endpoint in patients with myelofibrosis |
|
|
|
|
|
Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint
in Second Phase III Study |
|
|
|
|
|
Bruker Announces Launch of High Performance GC CARE Gas
Chromatography Column Product Line to Complement Laboratory GC
Instruments Business |
|
|
|
|
03/14/11 |
Thermo Fisher Scientific Extends Legacy of Innovation at Pittcon 2011 |
|
|
|
|
|
|
|
|
|
|
|
Amgen Donates $1 Million to Help Japanese Disaster
Victims |
|
|
|
|
03/11/11 |
Gilead Recommends Rejection of Mini-Tender Offer By TRC Capital
Corporation |
|
|
|
|
03/08/11 |
BMS:
FDA Accepts New Drug Application for Investigational
Compound Dapagliflozin for the Treatment of Type 2 Diabetes |
|
|
|
|
03/07/11 |
Proteome
Software today released Scaffold PTM |
|
|
|
|
03/04/11 |
U.S. FDA Removes Warning about Potential Liver Injury
from Boxed Warning of Prescribing Information for Gilead's Letairis |
|
|
|
|
|
Bayer extends support to fight Chagas disease
|
|
|
Amgen Completes Acquisition of BioVex
|
|
|
|
|
03/03/11 |
Caliper's Microfluidic Technologies Enable 510(k)
Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment |
|
|
|
|
03/02/11 |
Roche:
European Commission continues to support Avastin in
combination with paclitaxel as an effective treatment option for women
with metastatic breast cancer |
|
|
|
|
03/01/11 |
Myriad Announces New $100 Million Share Repurchase
Program |
|
|
|
|
|
Thermo Fisher Scientific Accelerates Expansion in China |
|
|
|
|
|
ESI Source Solutions:
A recent study using the Power Relay to control ABIRD demonstrated an
18% increase in proteins identified with ABIRD! |
|
|
|
|
02/28/11 |
|
|
|
|
|
02/24/11 |
FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast
Cancer in the United States |
|
|
|
|
|
Bruker Announces Agreement to Acquire Michrom, a Provider
of Nanoflow UHPLC Systems and CaptiveSpray Sources for Proteomics |
|
|
|
|
|
Thermo Fisher Scientific Signs Agreements to Sell Athena
Diagnostics and Lancaster Laboratories Businesses for a Total of $940
Million |
|
|
|
|
|
FDA Grants Genentech a Hearing on Avastin's Use for
Metastatic Breast Cancer in the United States |
|
|
|
|
|
Agilent's NMR Spectrometer Chosen by Harvard Medical
School Laboratory for Biomolecular Applications |
|
|
|
|
02/22/11 |
Gilead Sciences to Acquire Calistoga Pharmaceuticals for
$375 Million |
|
|
|
|
02/21/11 |
Nordion Signs Share Purchase Agreement to Divest MDS
Nordion S.A. |
|
|
|
|
02/18/11 |
Novartis gains positive CHMP opinion for Rasilamlo(TM), a
single-pill combination of aliskiren and amlodipine to treat high blood
pressure |
|
|
|
|
02/17/11 |
BMS
ABILIFY® (aripiprazole) Approved for Maintenance
Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or
Valproate |
|
|
|
|
02/15/11 |
Thermo Fisher Scientific Extends Cash Tender Offer for
Dionex Corporation |
|
|
|
|
02/14/11 |
Thermo Fisher Scientific Prices Offering of Senior Notes |
|
|
|
|
02/11/11 |
First African country introduces GSK’s pneumococcal
vaccine through innovative financing mechanism |
|
|
|
|
|
Genentech: Lucentis Phase III Study Meets Primary
Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME) |
|
|
|
|
02/09/11 |
Myriad's PROLARIS(TM) Test Shown to Significantly Predict
Prostate Cancer Outcome |
|
|
|
|
02/08/11 |
Third phase III study of Avastin-based regimen met
primary endpoint in ovarian cancer |
|
|
|
|
02/07/11 |
Abbott Introduces Biothreat Assay for PLEX-ID™ System |
|
|
|
|
|
Bruker Launches pTD(TM), a Compact, Lab Chip-based, Fully
Automated and Fast Toxin ID System for Homeland Security |
|
|
|
|
02/02/11 |
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two
Phase III Lung Cancer Trials of Necitumumab |
|
|
|
|
01/31/11 |
FDA approves the Novartis quadrivalent meningococcal
conjugate vaccine, Menveo®, for use in children from 2 years of age |
|
|
|
|
01/24/11 |
Thermo Fisher Scientific Notifies Holders of 3.25 Percent
Convertible Notes of Option to Require the Company to Purchase Notes |
|
|
|
|
|
Novartis gains approval for Gilenya® as a first-line
disease modifying oral therapy for multiple sclerosis in Switzerland and
Australia |
|
|
|
|
|
GlaxoSmithKline announces start of two phase III studies
in advanced/metastatic melanoma |
|
|
|
|
|
Amgen to Acquire BioVex, a Privately Held Biotechnology
Company Headquartered in Woburn, Mass |
|
|
|
|
01/21/11 |
Biogen Idec Receives Negative Opinion from the CHMP on
FAMPYRA |
|
|
|
|
01/19/11 |
Roche personalized investigational medicine shows
survival benefit in advanced skin cancer |
|
|
|
|
01/18/11 |
Genentech Personalized Investigational Medicine Shows
Survival Benefit in Advanced Skin Cancer |
|
|
|
|
|
Boehringer Ingelheim to Purchase Amgen's Fremont
(California) Facility |
|
|
|
|
01/14/11 |
Thermo Fisher Scientific Extends Cash Tender Offer for
Dionex Corporation |
|
|
|
|
01/03/11 |
|
|
|
|
|
01/02/11 |
|
|
|
|
|
12/27/10 |
Thermo Fisher Scientific Completes Acquisition of Lomb
Scientific |
|
|
|
|
12/23/10 |
|
|
|
|
|
|
US FDA Approves New Indication for Merck's HPV Vaccine,
GARDASIL® |
|
|
|
|
12/22/10 |
Gilead Terminates Phase III Clinical Trial of Ambrisentan
in Patients with Idiopathic Pulmonary Fibrosis |
|
|
|
|
|
Amylin and Lilly Seek Expanded Use of BYETTA® Along with
Basal Insulin |
|
|
|
|
12/20/10 |
Gilead Sciences to Acquire Arresto Biosciences for $225
Million |
|
|
|
|
12/16/10 |
Genentech Provides Update on Avastin for Metastatic
Breast Cancer Following Reviews in Europe and the United States |
|
|
|
|
12/13/10 |
John Fenn Dead at 93 |
|
|
|
|
|
Thermo Fisher Scientific to Acquire Dionex Corporation |
|
|
|
|
|
Roche announces change in Board of Directors |
|
|
|
|
|
GSK to strengthen Nutritional Healthcare business with
acquisition of Maxinutrition |
|
|
|
|
|
Bruker Receives Order from the University of Utrecht for
a Novel 527 GHz Solid State DNP-NMR System for Research on Membrane
Proteins and Protein Complexes |
|
|
|
|
|
Bayer CropScience and Evogene Sign Collaboration
Agreement to Improve Wheat Seed |
|
|
|
|
12/12/10 |
Geron Corporation Announces Closing of its Public
Offering of Common Stock |
|
|
|
|
12/09/10 |
Study of Novartis drug Zometa for potential new use in
early breast cancer did not meet primary endpoint in overall study
population |
|
|
|
|
|
Caliper Life Sciences to Acquire Cambridge Research &
Instrumentation |
|
|
|
|
|
Life Technologies Prices Offering of Senior Notes |
|
|
|
|
12/08/10 |
Myriad Acquires Novel Technology From Melanoma
Diagnostics |
|
|
|
|
12/07/10 |
GSK signs agreement to acquire Nanjing MeiRui
Pharmaceuticals in China |
|
|
|
|
|
Geron Corporation Announces the Pricing of Its Public
Offering of Common Stock |
|
|
|
|
|
Merck Prices $2.0 Billion Debt Offering |
|
|
|
|
12/06/10 |
Novartis:
Longer-term Phase III data show Novartis drug Tasigna®
continues to surpass Glivec® in slowing disease progression in patients
with newly diagnosed CML |
|
|
|
|
12/05/10 |
Roche:
Phase III study showed Rituxan/MabThera for initial use
followed by continued use delayed need for additional therapy in people
with asymptomatic follicular lymphoma, a common type of blood cancer |
|
|
|
|
|
Amgen's Nplate(R) Maintains Platelet Counts for More Than
Five Years in Adults With Chronic ITP |
|
|
|
|
12/02/10 |
Merck to Acquire SmartCells, Inc. |
|
|
|
|
11/30/10 |
Thermo Fisher Scientific Signs Definitive Agreement to
Acquire Lomb Scientific |
|
|
|
|
11/29/10 |
Government patent box proposals ‘transform’ UK
attractiveness for investment |
|
|
|
|
|
Life Technologies Launches Next-Generation DNA and RNA
Quantitation System |
|
|
|
|
|
GlaxoSmithKline to increase its shareholding in
Theravance |
|
|
|
|
|
Agilent Technologies Awarded $1.8 Million Contract by
U.S. Navy for Handheld Spectrum Analyzers |
|
|
|
|
11/26/10 |
GlaxoSmithKline and JSC Binnopharm enter vaccine
production alliance in Russia |
|
|
|
|
11/23/10 |
Roche obtains license for EGFR lung cancer assays and
will develop Tarceva companion diagnostic test |
|
|
|
|
|
Lilly and Acrux Receive FDA Approval for Axiron®
(Testosterone) Topical Solution CIII |
|
|
|
|
11/22/10 |
Abbott Announces Positive Results from Phase 2 Study of
Low Dose Atrasentan for Treatment of Diabetic Kidney Disease |
|
|
|
|
11/21/10 |
|
|
|
|
|
11/18/10 |
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the
Prevention of Skeletal-Related Events in Patients with Bone Metastases
from Solid Tumors |
|
|
|
|
11/17/10 |
GSK:
Human Genome Sciences and GlaxoSmithKline announce vote
of FDA advisory committee to recommend approval of Benlysta® for
systemic lupus erythematosus |
|
|
|
|
11/11/10 |
Life Technologies Launches EZValidation(TM) Online Tool
for Clinical Laboratory Market |
|
|
|
|
11/11/10 |
Abbott Awards Scholarships to Students Living with Cystic
Fibrosis to Help Them Pursue Their Dreams |
|
|
|
|
|
Geron Announces Two Publications Demonstrating That Its
Telomerase Inhibitor Drug Targets Cancer Stem Cells |
|
|
|
|
11/10/10 |
Incyte's Selective Oral JAK1 and JAK2 Inhibitor
Demonstrates Positive Phase IIa Results in Patients with Active
Rheumatoid Arthritis |
|
|
|
|
11/02/10 |
Bayer:
New molecules for efficient insect control:
Bayer CropScience, SentiSearch and leading US
Universities enter research cooperation » more |
|
|
|
|
|
Incyte Achieves $50 Million in Milestones for Initiation
of a Joint Global Phase III Clinical Trial of Novel JAK1 and JAK2
Inhibitor INCB18424 in Patients with Polycythemia Vera |
|
|
|
|
|
Geron Awarded Grants Under Qualifying Therapeutic
Discovery Project Program |
|
|
|
|
10/30/10 |
Novartis drug Afinitor® approved by FDA as first
medication for children and adults with a benign brain tumor associated
with tuberous sclerosis |
|
|
|
|
10/29/10 |
GlaxoSmithKline receives approval in Japan for two
medicines: Revolade and Xyzal |
|
|
|
|
10/26/10 |
GSK completes previously reported settlement with U.S.
Department of Justice regarding former manufacturing plant |
|
|
|
|
|
MDS Inc. Completes Name Change to Nordion Inc., and
Corresponding Change to Stock Ticker Symbols |
|
|
|
|
10/20/10 |
FDA Approves Herceptin For HER2-Positive Metastatic
Stomach Cancer |
|
|
|
|
09/29/10 |
BBGes and GeneBio develop accurate mass LC-MSMS spectra
library of drugs with SmileMS |
|
|
|
|
09/15/10 |
Novartis JAK inhibitor provides marked and durable
clinical benefits in patients with myelofibrosis, a rare,
life-threatening blood cancer |
|
|
|
|
09/13/10 |
Geron Obtains Exclusive License for Deriving Cartilage
from Human Embryonic Stem Cells from University of Edinburgh |
|
|
|
|
09/09/10 |
Thermo Fisher Scientific Announces Common Stock Buyback |
|
|
|
|
09/07/10 |
Bristol-Myers Squibb to Acquire ZymoGenetics |
|
|
|
|
|
University of Maryland School of Medicine Orders a Bruker
950 MHz NMR System for Advanced Molecular Medicine and Structural
Biology Research |
|
|
|
|
|
Bruker Announces 900 MHz NMR Systems Order from the
National Institute of Standards and Technology (NIST) for Molecular
Structure and Dynamics Research |
|
|
|
|
09/03/10 |
Novartis and collaborators discover novel antimalarial
drug candidate |
|
|
|
|
08/18/10 |
Wall Street Journal: The Avastin mugging |
|
|
|
|
08/11/10 |
Amgen Announces Top-Line Results of Phase 3 Head and Neck
Cancer Trial |
|
|
|
|
07/30/10 |
Geron to Proceed with First Human Clinical Trial of
Embryonic Stem Cell-Based Therapy |
|
|
|
|
07/28/10 |
Abbott Fund-Sponsored Laboratory Training Initiative
Helps Stem Critical Shortage of Medical Professionals in California |
|
|
|
|
07/23/10 |
Sandoz leads the way with first generic version of 'gold
standard' anti-thrombotic Lovenox®[1] |
|
|
|
|
07/20/10 |
Genentech Provides Update From Avastin FDA Advisory
Committee Meeting |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
